Alternatives to PAIN Act
- Sponsor
- Rep. Miller-Meeks, Mariannette [R-IA-1]
- Committees
- Ways and Means Committee (primary)
- Last action
- Feb 12, 2025
Bottom line
The bill aims to enhance access to non-opioid pain management options for Medicare beneficiaries by reducing out-of-pocket costs and removing administrative hurdles, thereby supporting efforts to combat the opioid crisis.
What it actually does
This bill amends Medicare Part D to eliminate deductibles and mandate the lowest cost-sharing tier for qualifying non-opioid pain management drugs, starting January 1, 2026. It also prohibits Medicare Part D and MA-PD plans from imposing step therapy requirements that mandate opioid use or any prior authorization requirements for these specific non-opioid drugs.
Proponents argue
Supporters argue that this legislation will directly address the opioid crisis by making non-addictive pain management more accessible and affordable for Medicare beneficiaries. They contend that removing financial and administrative barriers will encourage the use of non-opioid alternatives, reducing the likelihood of opioid dependence and improving patient care by empowering physicians and patients to choose appropriate treatments.
Opponents contend
Potential opponents might raise concerns about the increased costs to the Medicare program and Part D plans due to reduced patient cost-sharing and the removal of utilization management tools. They could argue that this might lead to higher premiums for all beneficiaries or increased taxpayer burden, and that removing prior authorization could lead to over-prescription of certain non-opioid drugs.
The bill is concise and its provisions are clearly stated, allowing for a quick and comprehensive understanding of its core changes.
Section 2(a)(1)(A), (B), (C) and (2) of the bill, amending Section 1860D-2(b) and (c) of the Social Security Act.
Exempting Qualifying Non-Opioid Pain Management Drugs from Part D Deductibles
For plan years beginning on or after January 1, 2026, Medicare Part D plans will no longer apply a deductible to drugs that meet the definition of a 'qualifying non-opioid pain management drug.' This means beneficiaries will not have to pay the full cost of these specific drugs up to their deductible amount before their insurance coverage begins to pay.
Supporters argue
Supporters argue this provision directly lowers a significant financial barrier for beneficiaries, making non-opioid pain relief a more accessible and affordable option compared to potentially cheaper, but addictive, opioids, thereby encouraging their use.
Critics contend
Opponents might argue that removing deductibles for a specific class of drugs could increase overall Medicare Part D spending, potentially leading to higher premiums for all beneficiaries or increased government subsidies.
Tradeoffs
This provision balances the goal of reducing opioid dependence by making non-opioids more accessible against potential increases in overall program costs or shifts in financial burden to plans and taxpayers.
Section 2(a)(1)(C) and (2) of the bill, amending Section 1860D-2(b) and (c) of the Social Security Act.
Mandating Lowest Cost-Sharing Tier for Qualifying Non-Opioid Pain Management Drugs
Starting January 1, 2026, Medicare Part D plans must place qualifying non-opioid pain management drugs on the lowest cost-sharing tier available. This ensures that beneficiaries pay the minimum possible co-insurance or co-payment for these drugs, further reducing their out-of-pocket expenses.
Section 2(a)(1)(C) of the bill, adding Section 1860D-2(b)(10)(B) to the Social Security Act.
Defining 'Qualifying Non-Opioid Pain Management Drug'
This section defines a 'qualifying non-opioid pain management drug' as a drug or biological product that is FDA-approved for acute pain, does not act on opioid receptors, has no therapeutically equivalent generic or competitor sold in the U.S., and whose monthly wholesale acquisition cost does not exceed a 'specialty-tier cost threshold' determined by the Secretary.
Section 2(b) of the bill, amending Section 1860D-14(a) of the Social Security Act.
Conforming Amendments for Low-Income Medicare Part D Beneficiaries
This section makes necessary adjustments to ensure that the new cost-sharing rules for qualifying non-opioid pain management drugs (no deductible, lowest cost-sharing tier) also apply to low-income Medicare Part D beneficiaries who receive additional subsidies, ensuring equitable access.
Section 3(2) of the bill, adding Section 1860D-4(c)(8)(A)(i) to the Social Security Act.
Prohibition on Opioid-First Step Therapy for Non-Opioid Pain Management Drugs
Effective January 1, 2026, Medicare Part D and MA-PD plans are prohibited from requiring a beneficiary to use an opioid drug before they can receive coverage for a qualifying non-opioid pain management drug. This removes a common administrative barrier to accessing non-addictive alternatives.
Section 3(2) of the bill, adding Section 1860D-4(c)(8)(A)(ii) to the Social Security Act.
Prohibition on Prior Authorization for Qualifying Non-Opioid Pain Management Drugs
As of January 1, 2026, Medicare Part D and MA-PD plans are prohibited from requiring prior authorization for qualifying non-opioid pain management drugs. This means patients can receive these drugs without their doctor needing to get advance approval from the plan, streamlining access.
This clause restricts the definition of a 'qualifying non-opioid pain management drug' to only those drugs that are novel (no therapeutically equivalent generic available in the US) and whose wholesale acquisition cost (WAC) does not exceed a Secretary-determined 'monthly specialty-tier cost threshold.'
Section 2(a)(1)(C), adding Section 1860D-2(b)(10)(B) to the Social Security Act.
Why it matters:This level of detail is standard for defining eligibility criteria in legislative text. It is not necessarily evasive but requires careful reading to understand the precise scope and limitations of the bill's benefits.
Case for: Supporters would argue this ensures the benefit is targeted at truly innovative, non-generic, and potentially higher-cost non-opioid drugs that might otherwise be financially out of reach, without opening the door to all non-opioid drugs, including cheaper generics. It aims to incentivize innovation in this specific area while managing overall program costs.
Case against: Critics might contend that this narrow definition limits the bill's impact, as many effective non-opioid pain management drugs might have generic equivalents or exceed the yet-to-be-defined cost threshold, thus not receiving the favorable cost-sharing and utilization management treatment. This could reduce the overall effectiveness in shifting away from opioids.
Estimated impact: This clause significantly limits the number of drugs that will qualify for the enhanced benefits, potentially reducing the overall fiscal impact of the bill on Medicare Part D plans, but also limiting the scope of patient access to a broader range of non-opioid options.